Physician profile
Abbas Motazedi
NPI 1962572644
$31,203.14
in general payments reported to CMS, 2019-2025
40 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,617 · 2021: $6,205 · 2022: $1,945 · 2023: $3,973 · 2024: $1,994 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,150 · Consulting Fee: $175 · Travel and Lodging: $24.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,474.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,150.00 |
| Consulting Fee | $175.00 |
| Travel and Lodging | $24.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,797.11 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,079.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,560.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amneal Pharmaceuticals LLC | $1,288.18 | 2021-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $952.04 | 2021-2025 | |
| Amgen INC. | $762.05 | 2019-2025 | Prolia, Repatha, Tepezza |
| Sanofi-Aventis U.S. LLC | $723.70 | 2019-2025 | |
| Insulet Corporation | $679.93 | 2019-2025 | Omnipod |
| Abbvie INC. | $511.68 | 2019-2025 | |
| Abbott Laboratories | $397.12 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $361.89 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $315.45 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $193.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.15 | 2019-2021 | |
| Novo Nordisk INC | $138.41 | 2019-2025 | Wegovy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Motazedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.